Breadcrumbs

Melanoma - oncology

Adjuvant

Protocol Administration at chemotherapy unit level Review date
Melanoma adjuvant nivolumab (weight based dosing)
Low June 2022
Melanoma adjuvant nivolumab (flat dosing)
(for information on this protocol please contact the SA Health Cancer Drug Committee)
Low  June 2020

Metastatic

Protocol Administration at chemotherapy unit level Review date
Melanoma metastatic binimetinib and encorafenib4 
Low September 2022
Melanoma metastatic cobimetinib and vemurafenib
Low June 2022
Melanoma metastatic dabrafenib
(for more information on this protocol please email the SA Health Cancer Drug Committee)
Low September 2022
Malignant melanoma metastatic dabrafenib and trametinib Low June 2022
Melanoma metastatic ipilimumab Low September 2020
Melanoma metastatic ipilimumab and nivolumab (induction) Medium September 2020
Melanoma metastatic nivolumab (flat dosing)
Low June 2022
Melanoma metastatic pembrolizumab (flat dosing)
Low September 2022
Melanoma metastatic pembrolizumab (weight based dosing)
Low September 2022
Melanoma metastatic nivolumab (weight based dosing) Low June 2022
Melanoma metastatic nivolumab (maintenance) following ipilimumab and nivolumab Low September 2022

Non-melanoma

Protocol Administration at chemotherapy unit level Review date
Basal cell carcinoma locally advanced or metastatic sonidegib
Low March 2022
Basal cell carcinoma locally advanced or metastatic vismodegib
Low December 2021
Merkel cell carcinoma metastatic avelumab
Medium September 2022

  1. Permitted to be administered in low-risk units for second and subsequent cycles for patients with ECOG performance status 0 or 1 showing ≤ Grade 1 toxicity
  2. Fluorouracil pumps may be connected/disconnected at low-risk units
  3. Local radiotherapy services required
  4. Non-formulary drug included in the protocol
  5. Continuation dual treatment with pertuzumab and trastuzumab can be provided to appropriate patients at low-risk chemotherapy units.

^ Back to top